The findings provide valuable insight as to why some cancers metastasize to bone, and could eventually result in new metastasis-prevention drugs, said Laurie McCauley, professor in the Department of Periodontics and Oral Medicine at the University of Michigan School of Dentistry and principal investigator on the study.
The really good news is that researchers reversed the tumor-friendly effect of the drug, called cyclophosphamide, by inhibiting another cell-communicating protein in the bone marrow, called CCL2.
"This work is early and still at the pre-clinical level," said McCauley, who also has an appointment in the Department of Pathology at the U-M Health System. "However, the biggest potential impact is in metastasis preventive strategies.
"If we better understood the specific mediators, or conditions, in the bone marrow that support tumors, we could develop more effective therapeutics to prevent local cancers from spreading and hence reduce metastasis to the bone."
The study highlights the potential for the bone marrow to provide the right environment for tumors to metastasize, said Serk In Park, first author and a postdoctoral fellow in McCauley's lab. Many cancers, such as prostate and breast cancer, are fond of spreading, or metastasizing, to bones.
Researchers administered the chemotherapy drug cyclophosphamide experimentally to manipulate the environment inside the bone marrow prior to exposing experimental tumors. Cyclophosphamide therapy is used in certain cancers to slow cell growth, and McCauley's group experimented with its use in a pre-metastatic mode using a prostate cancer model.
While effective at attacking tumor cells, a side effect of cyclophosphamide (and many other chemotherapy drugs) is that it suppresses certain bone marrow cells that help the immune system and increases some harmful cells. Researchers hypothesized correctly that the drug would make the bone marrow more tumor-friendly.
The paper, "Cyclophosphamide Creates a Receptive Microenvironment for Prostate Cancer Skeletal Metastasis," appears in the journal Cancer Research.Laurie McCauley:
Laura Bailey | EurekAlert!
Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State
NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Life Sciences
08.12.2016 | Physics and Astronomy
08.12.2016 | Materials Sciences